Gene editing company Editas Medicine will reduce its workforce by 65% over the next six months as it focuses on in vivo CRISPR-edited medicines.
On Dec. 12, the Cambridge, Mass.-based company said several leaders, including Chief Medical Officer Baisong Mei, MD, PhD, will depart during this transition.
Editas said the restructuring will "extend its cash runway" into the second quarter of 2027 and "accelerate its intent to achieve in vivo human proof of concept in approximately two years."
The company also reported preclinical achievements in liver and blood stem cell research.